Perrigo Company (NYSE:PRGO) received a $60.00 target price from investment analysts at Royal Bank Of Canada in a research note issued to investors on Sunday. The firm presently has a “sell” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential downside of 18.78% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Deutsche Bank AG restated a “buy” rating and issued a $88.00 target price (up previously from $86.00) on shares of Perrigo in a research note on Monday. BidaskClub upgraded shares of Perrigo from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Cantor Fitzgerald began coverage on shares of Perrigo in a research note on Friday, June 16th. They issued an “overweight” rating and a $85.00 price objective for the company. ValuEngine cut shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Barclays PLC reiterated an “overweight” rating and issued a $85.00 price objective (down previously from $100.00) on shares of Perrigo in a research note on Thursday, June 1st. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $86.16.

Perrigo (PRGO) traded down 0.01% on Friday, reaching $73.87. 854,952 shares of the company were exchanged. The stock’s market capitalization is $10.59 billion. The stock has a 50-day moving average price of $72.86 and a 200 day moving average price of $74.84. Perrigo has a 52 week low of $65.47 and a 52 week high of $99.14.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Tuesday, May 30th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.06. Perrigo had a negative net margin of 43.81% and a positive return on equity of 11.79%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the firm posted $1.32 EPS. Perrigo’s revenue for the quarter was down 11.4% on a year-over-year basis. Analysts forecast that Perrigo will post $4.28 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/17/perrigo-company-prgo-given-a-60-00-price-target-by-royal-bank-of-canada-analysts.html.

Several large investors have recently modified their holdings of PRGO. Cornerstone Capital Management LLC increased its stake in shares of Perrigo by 4.0% in the second quarter. Cornerstone Capital Management LLC now owns 547,968 shares of the company’s stock worth $49,684,000 after buying an additional 20,896 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Perrigo during the second quarter worth approximately $210,657,000. Accident Compensation Corp purchased a new stake in shares of Perrigo during the fourth quarter worth approximately $7,954,000. Aperio Group LLC increased its stake in shares of Perrigo by 49.5% in the first quarter. Aperio Group LLC now owns 26,238 shares of the company’s stock worth $3,357,000 after buying an additional 8,685 shares during the period. Finally, Mariner Wealth Advisors LLC increased its stake in shares of Perrigo by 39.3% in the first quarter. Mariner Wealth Advisors LLC now owns 10,784 shares of the company’s stock worth $1,380,000 after buying an additional 3,045 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.